Dexrazoxane for the treatment of chemotherapy-related side effects

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Dexrazoxane for the treatment of chemotherapy-related side effects. / Langer, Seppo W.

I: Cancer Management and Research, Bind 6, 2014, s. 357-63.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Langer, SW 2014, 'Dexrazoxane for the treatment of chemotherapy-related side effects', Cancer Management and Research, bind 6, s. 357-63. https://doi.org/10.2147/CMAR.S47238

APA

Langer, S. W. (2014). Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Management and Research, 6, 357-63. https://doi.org/10.2147/CMAR.S47238

Vancouver

Langer SW. Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Management and Research. 2014;6:357-63. https://doi.org/10.2147/CMAR.S47238

Author

Langer, Seppo W. / Dexrazoxane for the treatment of chemotherapy-related side effects. I: Cancer Management and Research. 2014 ; Bind 6. s. 357-63.

Bibtex

@article{9522927e53ff47f0aa9887b30deb8902,
title = "Dexrazoxane for the treatment of chemotherapy-related side effects",
abstract = "For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications. ",
author = "Langer, {Seppo W}",
year = "2014",
doi = "10.2147/CMAR.S47238",
language = "English",
volume = "6",
pages = "357--63",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd",

}

RIS

TY - JOUR

T1 - Dexrazoxane for the treatment of chemotherapy-related side effects

AU - Langer, Seppo W

PY - 2014

Y1 - 2014

N2 - For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.

AB - For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.

U2 - 10.2147/CMAR.S47238

DO - 10.2147/CMAR.S47238

M3 - Review

C2 - 25246808

VL - 6

SP - 357

EP - 363

JO - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

ER -

ID: 247891061